{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/candida-female-genital/management/diabetes-or-immunocompromised/","result":{"pageContext":{"chapter":{"id":"0f525c4d-623c-5b02-9045-c7f9c57692e4","slug":"diabetes-or-immunocompromised","fullItemName":"Scenario: Diabetes or immunocompromised","depth":2,"htmlHeader":"<!-- begin field 7d24b1a5-3a79-40d1-94fd-884da81b0380 --><h2>Scenario: Diabetes or immunocompromised</h2><!-- end field 7d24b1a5-3a79-40d1-94fd-884da81b0380 -->","summary":"Covers the management of vulvovaginal candidiasis in women who have diabetes mellitus or are immunocompromised.","htmlStringContent":"<!-- begin item 933e433e-e36d-4788-b573-e0382080152c --><!-- begin field ca83bc17-e91d-4239-980f-acbc0156a9ca --><p>From age 12 years onwards (Female).</p><!-- end field ca83bc17-e91d-4239-980f-acbc0156a9ca --><!-- end item 933e433e-e36d-4788-b573-e0382080152c -->","topic":{"id":"99e20f18-68df-560d-b5d3-b6ec31ccad61","topicId":"1a8f74c5-56a3-4356-a328-97bd2f790f35","topicName":"Candida - female genital","slug":"candida-female-genital","lastRevised":"Last revised in May 2017","chapters":[{"id":"de1ba63a-d3be-5e38-9afa-2decfb6a4104","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"70e5dc95-dca6-5aed-ba02-7677e5595791","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"7785eebb-7adf-5829-8438-054465d94780","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"17acaa38-dc82-5062-9b9e-b70e43844f09","slug":"changes","fullItemName":"Changes"},{"id":"3fde567e-3066-57d8-be3e-016c389f8b94","slug":"update","fullItemName":"Update"}]},{"id":"7bdd785b-dd70-5bde-a56b-ece7a71c1890","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"2aea51d9-2817-5901-8b3f-003e41a1f1b9","slug":"goals","fullItemName":"Goals"},{"id":"16c71775-c8a9-58f1-b6e8-00d83ea3e32a","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"584f77ef-93e6-5c84-93b4-8331fed80193","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"ffb6e4fa-b86a-5191-9bbb-c113c86952b6","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"cc13b04c-c8b4-5403-a61e-10f784bc17de","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"8ba1a16f-d8bd-55bc-8208-17beaddd9264","slug":"nice-quality-standards","fullItemName":"NICE Quality standards"}]},{"id":"d90c278f-fcf0-5c7c-aeab-b0decc2194dd","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"5d851a40-f1f9-50de-b7de-3e374a862b45","slug":"definition","fullItemName":"Definition"},{"id":"51060b0d-4f1d-5133-9645-6efc6b9ca9d8","slug":"prevalence","fullItemName":"Prevalence"},{"id":"c7dd35c5-dc87-55a0-b15e-5fd3c5f79ede","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"bcbc381a-db1c-5df4-a8fa-cb1ce02a4ab3","slug":"complications","fullItemName":"Complications"},{"id":"2ec519a6-61da-53cb-b5c6-e53420e1f175","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"1296609f-72a1-5634-918b-eb0f9bf2b217","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"197fc582-d823-5341-813b-4d48a895ac84","slug":"assessment","fullItemName":"Assessment"},{"id":"7fa609e6-64b1-5e1e-a2fe-9d8aaae57662","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"b7ed2787-e953-5da0-ba29-6ad5d5aa7138","fullItemName":"Management","slug":"management","subChapters":[{"id":"0d8e43cc-e312-572a-97eb-50ab1223bf29","slug":"uncomplicated-infection","fullItemName":"Scenario: Uncomplicated infection"},{"id":"20ef6f32-4f35-577b-af2b-0479dafd7a6f","slug":"severe-infection","fullItemName":"Scenario: Severe infection"},{"id":"19018671-1df6-546c-a24e-c0277342e2e1","slug":"recurrent-infection","fullItemName":"Scenario: Recurrent infection"},{"id":"0f525c4d-623c-5b02-9045-c7f9c57692e4","slug":"diabetes-or-immunocompromised","fullItemName":"Scenario: Diabetes or immunocompromised"},{"id":"d143d272-2856-5fad-95fe-708b221847f0","slug":"during-pregnancy","fullItemName":"Scenario: During pregnancy"}]},{"id":"fa8e2e27-5ea4-5088-86f8-65ffd101ec26","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"a11071ae-b868-56f6-a390-4809b91594ea","slug":"choice-of-antifungals","fullItemName":"Choice of antifungals"},{"id":"169ff7be-fabd-556e-bdf3-92c30e390f3d","slug":"intravaginal-antifungals","fullItemName":"Intravaginal antifungals"},{"id":"cca352b0-a363-5b43-97d2-9df0dbf242b6","slug":"oral-fluconazole","fullItemName":"Oral fluconazole"},{"id":"754e0483-3f11-5510-9b98-7f8c44679e56","slug":"oral-itraconazole","fullItemName":"Oral itraconazole"},{"id":"2ae3a41b-64fa-5372-baba-bb8c04e033d8","slug":"topical-antifungals","fullItemName":"Topical antifungals"}]},{"id":"dd75ee8e-5efd-51c0-bcc2-3af7ee1253e7","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"74d9d85c-590f-5e29-a202-78d94a6f747f","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"d7a69713-bc5d-57da-9132-ff07c7fef62c","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"a8d93477-c70c-5177-92d7-e96545a6b2f7","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"4841d69e-1e2b-5aec-9c3b-1ea8cd8bbf08","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"b3113b9f-1b0e-5987-99b4-e616eb6d128a","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"0e41c5da-d9a8-5c0d-bb7f-f68cda4acb05","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"6eb1b4a4-5ae4-5a59-8ca6-6434652b9454","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"b7ed2787-e953-5da0-ba29-6ad5d5aa7138","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"7f00bc9a-076c-59eb-acf4-23c189f37614","slug":"initial-management","fullItemName":"Initial management","depth":3,"htmlHeader":"<!-- begin field 1545353f-8934-4021-ab85-bd8250e06cab --><h3>How should I manage a person with vulvovaginal candidiasis who is diabetic or immunocompromised?</h3><!-- end field 1545353f-8934-4021-ab85-bd8250e06cab -->","summary":null,"htmlStringContent":"<!-- begin item 3f87b810-2594-4713-9980-e6121088a58c --><!-- begin field c1801e4c-4aa1-4dd9-a776-600405fac089 --><p><strong>For people with controlled diabetes or HIV,</strong> manage uncomplicated, severe, and recurrent infections as for women without diabetes or HIV. See <a class=\"topic-reference internal-reference\" href=\"/topics/candida-female-genital/management/uncomplicated-infection/\">Scenario: Uncomplicated infection</a>, <a class=\"topic-reference internal-reference\" href=\"/topics/candida-female-genital/management/severe-infection/\">Scenario: Severe infection</a>, and <a class=\"topic-reference internal-reference\" href=\"/topics/candida-female-genital/management/recurrent-infection/\">Scenario: Recurrent infection</a> for more information.</p><p><strong>For people with uncontrolled diabetes or HIV and those taking immunosuppressive drugs (such as oral corticosteroids):</strong></p><ul><li><strong>Correct modifiable conditions (such as uncontrolled diabetes mellitus), where possible. </strong><ul><li>See the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/diabetes-type-1/\">Diabetes - type 1</a> and <a class=\"topic-reference external-reference\" href=\"/topics/diabetes-type-2/\">Diabetes - type 2</a> for more information.</li></ul></li><li><strong>Prescribe antifungal treatment.</strong><ul><li>The choice of treatment and formulation will depend on factors such as contraindications and cautions, the licenced age and indication for the product, and the person's preference.<ul><li><strong>For most women, </strong>prescribe an <a class=\"topic-reference internal-reference\" href=\"/topics/candida-female-genital/management/diabetes-or-immunocompromised/#extended-courses-of-antifungals\">extended course</a> of an intravaginal antifungal (clotrimazole, econazole, or miconazole) or oral antifungal (fluconazole or itraconazole).</li><li><strong>For women aged 60 years and older,</strong> oral antifungals may be more acceptable because of the ease of administration.</li><li><strong>For girls aged 12–15 years, </strong>refer or seek specialist advice.</li><li><strong>For breastfeeding women, </strong>consider treating with an <a class=\"topic-reference internal-reference\" href=\"/topics/candida-female-genital/management/diabetes-or-immunocompromised/#extended-courses-of-antifungals\">extended course</a> intravaginal clotrimazole or miconazole, or seek specialist advice.</li></ul></li><li><strong>If there are vulval symptoms,</strong> consider prescribing a topical imidazole<em> </em>in addition to an oral or intravaginal antifungal. Options include:<ul><li>Clotrimazole 1% or 2% cream applied 2–3 times a day.</li><li>Ketoconazole 2% cream applied 1–2 times a day (for adults aged 18 years and older).</li></ul></li><li><strong>See the section </strong><strong>on <a class=\"topic-reference internal-reference\" href=\"/topics/candida-female-genital/prescribing-information/\">Prescribing information</a> for detailed information on</strong> intravaginal, oral, and topical antifungals, including information on contraindications and cautions, adverse effects, and drug interactions.</li><li><strong>Be aware that</strong> intravaginal clotrimazole, oral fluconazole, and topical clotrimazole can be purchased over-the-counter.</li></ul></li><li><strong>Advise the woman:</strong><ul><li>To return if symptoms have not resolved within 7–14 days. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/candida-female-genital/management/diabetes-or-immunocompromised/#managing-treatment-failure\">Managing&nbsp;treatment failure</a> for more management information.</li><li>On measures to aid symptom relief and prevent recurrence. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/candida-female-genital/management/diabetes-or-immunocompromised/#general-advice-on-self-management\">Self-management advice</a> for more information.</li></ul></li><li> <strong>Follow-up and test of cure are <em>not</em> necessary if symptoms resolve</strong></li><li><strong>Do not routinely treat </strong><strong>an asymptomatic sexual partner.</strong><ul><li>If the male partner of a woman with vulvovaginal candidiasis has balanitis (characterized by erythematous areas on the glans of the penis, pruritus, and/or irritation), see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/balanitis/\">Balanitis</a> for management information.</li></ul></li></ul><!-- end field c1801e4c-4aa1-4dd9-a776-600405fac089 --><!-- end item 3f87b810-2594-4713-9980-e6121088a58c -->","subChapters":[{"id":"4bdb85d0-f563-53ec-b8b7-9cc989b9179e","slug":"extended-courses-of-antifungals","fullItemName":"Extended courses of antifungals","depth":4,"htmlHeader":"<!-- begin field 75f5502b-8b81-4a37-a375-a6b400d1b74b --><h4>What extended courses of antifungals are recommended for managing vulvovaginal candidiasis in women with uncontrolled diabetes or HIV and those taking immunosuppressive drugs?</h4><!-- end field 75f5502b-8b81-4a37-a375-a6b400d1b74b -->","summary":null,"htmlStringContent":"<!-- begin item 0072dbd6-213f-41aa-a804-a6b400d1b5da --><!-- begin field 972866fd-a8bb-4b80-b8c5-a6b400d1b74b --><ul><li><strong>For intravaginal creams, provided there are no <a class=\"topic-reference internal-reference\" href=\"/topics/candida-female-genital/prescribing-information/intravaginal-antifungals/#prescribing-issues\">contraindications</a></strong><strong><em>,</em> the recommended extended treatments and doses are:</strong><ul><li><strong>Miconazole 2% cream </strong>— insert 5 g into the vagina once daily for 10–14 days, <em>or</em> 5 g into the vagina twice daily for 7 days.</li><li><strong>Econazole 1% cream </strong>— insert 5 g into the vagina and apply to vulva at night for at least 14 nights.</li></ul></li><li><strong>For intravaginal pessaries, provided there are no <a class=\"topic-reference internal-reference\" href=\"/topics/candida-female-genital/prescribing-information/intravaginal-antifungals/#prescribing-issues\">contraindications</a><em>,</em> the recommended extended treatments and doses are:</strong><ul><li><strong>Clotrimazole 100 mg pessaries </strong>— insert 1 pessary into the vagina once at night for 12 nights.</li><li><strong>Clotrimazole 200 mg pessaries (3 pessaries) </strong>— insert 1 pessary into the vagina once at night for 6 nights.</li><li><strong>Econazole nitrate 150 mg pessaries </strong>— insert 1 pessary into the vagina once at night for 6 nights (off-label use).</li></ul></li><li><strong>For oral fluconazole, provided there are no <a class=\"topic-reference internal-reference\" href=\"/topics/candida-female-genital/prescribing-information/oral-fluconazole/#contraindications-cautions\">contraindications</a>, the recommended extended course is</strong> 100 mg once a day for 7 days.</li><li><strong>For oral itraconazole, provided there are no <a class=\"topic-reference internal-reference\" href=\"/topics/candida-female-genital/prescribing-information/oral-itraconazole/#contraindications-cautions\">contraindications</a>, the recommended extended course is </strong>200 mg once a day for 7 days.</li></ul><!-- end field 972866fd-a8bb-4b80-b8c5-a6b400d1b74b --><!-- end item 0072dbd6-213f-41aa-a804-a6b400d1b5da -->","subChapters":[]},{"id":"a74517e4-9b9a-5c87-8989-fb788849931b","slug":"basis-for-recommendation-1c1","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 129f9e96-6cd6-46c8-9236-560186c54b32 --><h4>Basis for recommendation</h4><!-- end field 129f9e96-6cd6-46c8-9236-560186c54b32 -->","summary":null,"htmlStringContent":"<!-- begin item 1c11b92e-55b4-493c-b1c1-8b846e50bbd2 --><!-- begin field b5016720-9fb5-44da-aba1-3f08929c14ad --><h5>Managing women with diabetes mellitus or who are HIV positive</h5><ul><li><strong>Diabetes mellitus</strong><ul><li>Expert opinion in the British Society of Sexual Health and HIV (BASHH) <em>Guideline on the management of vulvovaginal candidiasis</em> is that for vulvovaginal <em>Candida albicans </em>infections, the response to oral fluconazole 150 mg is similar for both women with diabetes and women without [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">BASHH, 2007d</a>].</li><li>The US Centers for Disease Control and Prevention (CDC) recommends prolonged antifungal treatment (7–14 days) and correcting modifiable conditions (where possible) for women with underlying debilitating medical conditions (such as uncontrolled diabetes) and those receiving corticosteroid treatment, as they do not respond as well to short-term antifungal treatments [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">CDC, 2015</a>].</li></ul></li><li><strong>HIV positive</strong><ul><li>Expert opinion in guidelines [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">BASHH, 2007d</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">Nelson et al, 2011</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">CDC, 2015</a>] and a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">Sobel, 2007</a>] is that women with HIV and symptomatic vulvovaginal candidiasis (including recurrent infections) should be treated in an identical way to women who are not HIV positive.</li><li>However, vulvovaginal candidiasis does occur more frequently and is more likely to persist in HIV positive women [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">BASHH, 2007d</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">FSRH, 2012</a>], and longer courses of treatment may be required [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">FSRH, 2012</a>].</li></ul></li><li><strong>Extended courses of oral or intravaginal antifungal</strong><ul><li>The recommended intravaginal preparations (clotrimazole, econazole, and miconazole) are licensed for extended use [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">ABPI, 2015d</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">ABPI, 2015e</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">ABPI, 2015b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">ABPI, 2016a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">ABPI, 2016c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">ABPI, 2016d</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">BNF 72, 2016</a>].</li><li>Although itraconazole and fluconazole are licensed for short-term use (1 day) for the management of vulvovaginal candidiasis, they can safely be used (and are licensed) for longer durations (7 days or longer) to treat other fungal infections (such as pityriasis versicolor [7 days with itraconazole] and oropharyngeal candidiasis [7–21 days with fluconazole]) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">ABPI, 2015c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">ABPI, 2016b</a>].</li></ul></li></ul><h5>Managing women aged 60 years and older</h5><ul><li><p>This recommendation is based on expert opinion in a review article, which states that after alternative diagnoses have been excluded and risk factors removed (where possible), the investigation and treatment of vulvovaginal candidiasis in older women should be the same as for younger women. However, oral regimens are perhaps more acceptable because of the ease of administration and the avoidance of potentially messy creams and suppositories [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">Nwokolo and Boag, 2000</a>].</p></li></ul><h5>Managing girls aged 12–15 years</h5><ul><li>This recommendation is based on the fact that management decisions for this age group are not straightforward:<ul><li>Intravaginal antifungal pessaries and cream are not recommended for pre-pubertal girls [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">ABPI, 2015b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">ABPI, 2016a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">BNF for Children, 2017</a>].</li><li>The British National Formulary (BNF) for Children states that treatment with an external cream may be more appropriate in this age group [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">BNF for Children, 2017</a>]. CKS recommends arranging referral or seeking specialist advice as an external cream may be ineffective in this case.</li><li>Oral fluconazole is not licensed for treating vulvovaginal candidiasis in children younger than 16 years of age [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">ABPI, 2015c</a>].</li><li>Oral itraconazole is not licensed for use in children (age not specified by the manufacturer) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">ABPI, 2016b</a>].</li></ul></li></ul><h5>Managing breastfeeding women</h5><ul><li>CKS recommends intravaginal clotrimazole or miconazole as there is extensive experience with their use.</li><li>The manufacturer advises that breastfeeding is not recommended after high-dose treatment with (or repeated use of) oral fluconazole, except for potentially life-threatening infections [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">ABPI, 2015c</a>], and itraconazole is not recommended for use in breastfeeding women [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">ABPI, 2016b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">BNF 72, 2016</a>].</li></ul><h5>Managing vulval symptoms</h5><ul><li>This recommendation is based on the BNF, which states that vaginal applications may be supplemented with a topical antifungal cream for vulvitis and to treat other superficial sites of infection [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">BNF 72, 2016</a>].</li></ul><h5>Follow-up and test of cure not necessary </h5><ul><li><p>In the expert opinion of the British Association of Sexual Health and HIV (BASHH) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">BASHH, 2007b</a>] and the US Centers for Disease Control and Prevention (CDC) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">CDC, 2015</a>], follow up and test of cure are unnecessary unless symptoms are persistent or recurrent.</p></li></ul><h5>Advice</h5><ul><li>The recommendation to advise the person to return if symptoms have not resolved within 7–14 days is based on expert opinion in review articles, which states that treatment failure is considered to have occurred if symptoms do not resolve within 7–14 days of antifungal treatment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">Sobel et al, 1998</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">Watson et al, 2002</a>].</li><li>The recommendation to advise on measures to aid symptom relief is based on what CKS considers to be good clinical practice.</li></ul><h5>Not routinely treating an asymptomatic sexual partner</h5><ul><li>In the expert opinion of BASHH [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">BASHH, 2007b</a>] and the CDC [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">CDC, 2015</a>], uncomplicated vulvovaginal candidiasis is not usually acquired through sexual intercourse, and the available data do not support treating asymptomatic male partner of women with vulvovaginal candidiasis.</li><li>However, a small percentage of male partners will develop balanitis, and they should be managed appropriately [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">CDC, 2015</a>].</li></ul><h5>Treatments not recommended</h5><ul><li><p><strong>Oral ketoconazole</strong> — due to the increased risk of liver damage associated with its use, the European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) has suspended the marketing authorization for oral ketoconazole. It should no longer be prescribed for the treatment of fungal infections [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">MHRA, 2013a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">MHRA, 2013b</a>].</p></li></ul><!-- end field b5016720-9fb5-44da-aba1-3f08929c14ad --><!-- end item 1c11b92e-55b4-493c-b1c1-8b846e50bbd2 -->","subChapters":[]}]},{"id":"c539b27e-cb63-5cc3-8df0-fa99adb8575d","slug":"general-advice-on-self-management","fullItemName":"General advice on self-management","depth":3,"htmlHeader":"<!-- begin field 0e4c62cb-cdf6-4f58-bfca-8957b2949537 --><h3>What advice on self-management should I give?</h3><!-- end field 0e4c62cb-cdf6-4f58-bfca-8957b2949537 -->","summary":null,"htmlStringContent":"<!-- begin item cc75a898-a917-45d1-9983-3601591644d7 --><!-- begin field db7061e2-4313-48fb-a148-1590026b6bff --><ul><li><strong>Advise the woman to:</strong><ul><li>Avoid the following potential predisposing factors:<ul><li>Washing and cleaning the vulval area with soap or shower gels (including those containing perfume and antiseptics [such as tea tree oil]), wipes, and 'feminine hygiene' products.</li><li>Cleaning the vulval area more than once a day.</li><li>Washing underwear in biological washing powder and using fabric conditioners.</li><li>Vaginal douching.</li><li>Wearing tight-fitting and/or non-absorbent clothing.</li></ul></li><li>Wash the vulval area with a soap substitute — this should be used externally and not more than once a day.</li><li>Use a simple emollient to moisturise the vulval area.</li><li>Consider using probiotics (such as live yoghurts) orally or topically to relieve symptoms.  </li></ul></li></ul><!-- end field db7061e2-4313-48fb-a148-1590026b6bff --><!-- end item cc75a898-a917-45d1-9983-3601591644d7 -->","subChapters":[{"id":"f27de669-0aa5-5972-8d20-007764388900","slug":"basis-for-recommendation-13b","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field e0ae888a-22e3-4d5b-95e8-129aa8af6e83 --><h4>Basis for recommendation</h4><!-- end field e0ae888a-22e3-4d5b-95e8-129aa8af6e83 -->","summary":null,"htmlStringContent":"<!-- begin item 13b3fddc-b04b-44d2-9a89-453290246575 --><!-- begin field 824ef61f-8797-43e6-8875-804ea97dd515 --><h5>Avoiding potential predisposing factors</h5><ul><li>Expert opinion in UK guidelines is that local irritants (such as soaps, shower gels, and ‘feminine hygiene’ products) and tight fitting, synthetic clothing can predispose to (or exacerbate) symptomatic vulvovaginal candidiasis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">BASHH, 2007b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">RCGP, 2013</a>], although the evidence for these is limited, conflicting, or absent.</li><li>Evidence from observational studies suggests that vaginal douching increases the risk of infection and other adverse effects [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">Lopez, 2015</a>].</li></ul><h5>General care of the vaginal skin</h5><ul><li>The advice on the general care of vulval skin and the use of a simple emollient is based on expert advice in the Royal College of Obstetricians and Gynaecologists (RCOG) guideline <em>The management of vulval skin disorders</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">RCOG, 2011</a>].</li></ul><h5>Probiotics</h5><ul><li>The British Medical Journal (BMJ) Clinical Evidence review on <em>Vulvovaginal candidiasis</em> (search date: October 2013) did not identify any randomized controlled trials (RCTs) comparing yoghurt containing <em>Lactobacillus acidophilus </em>with other interventions for the treatment of women with acute vulvovaginal candidiasis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">Lopez, 2015</a>].<ul><li>One small RCT (n = 55) that compared oral <em>L acidophilus </em>with placebo at 1 month when given after a single dose of oral fluconazole (150 mg) found that oral <em>L acidophilus</em>:<ul><li>Decreased vaginal discharge compared with placebo (3/29 [10%] with oral <em>L acidophilus </em>compared with 9/26 [35%] with placebo; P = 0.03).</li><li>Reduced the presence of yeast detected by culture compared with placebo (3/29 [10%] with oral <em>L acidophilus </em>compared with 10/26 [39%] with placebo; P = 0.01).</li></ul></li><li>There was no evidence of serious harm, but one systematic review (which did not identify any suitable RCTs) stated that oral yoghurt may cause gastrointestinal disturbance in people with lactose intolerance.</li><li>The authors of the BMJ review concluded that the following should be considered:<ul><li>Applying yoghurt intravaginally may be embarrassing and uncomfortable for some women.</li><li>Although different yoghurts can be purchased, their compositions vary, and their effects may differ.</li><li>The effect of alterations in vaginal pH that may occur with intravaginal yoghurt use is unknown.</li></ul></li></ul></li><li>CKS recommends advising the woman to consider using probiotics because although there is no evidence that they are effective, there is no evidence of (or concerns about) serious adverse effects.</li></ul><h5>Tea tree oil</h5><ul><li>The BMJ Clinical Evidence review on <em>Vulvovaginal candidiasis</em> (search date: October 2013) did not identify any RCTs comparing intravaginal tea tree oil with other interventions for the treatment of women with acute vulvovaginal candidiasis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">Lopez, 2015</a>].<ul><li>One systematic review (which did not identify any suitable RCTs) stated that topical tea tree oil can cause skin irritation and a severe allergic rash.</li><li>One case report found that topical tea tree oil was associated with systemic hypersensitivity reaction.</li></ul></li><li>Expert opinion in the joint Faculty of Sexual and Reproductive Healthcare (FSRH) and the British Association of Sexual Health and HIV (BASHH) guideline <em>Management of vaginal discharge in non-genitourinary medicine settings</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">FSRH, 2012</a>] and the joint Royal College of General Practitioners (RCGP) Sex, Drugs and HIV Task Group and BASHH guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">RCGP, 2013</a>] is that there is currently insufficient evidence to recommend the use of tea tree oil in the management of vulvovaginal candidiasis.</li></ul><!-- end field 824ef61f-8797-43e6-8875-804ea97dd515 --><!-- end item 13b3fddc-b04b-44d2-9a89-453290246575 -->","subChapters":[]}]},{"id":"0a5c5ff9-8701-5144-b31d-0a6f0aa28271","slug":"managing-treatment-failure","fullItemName":"Managing treatment failure","depth":3,"htmlHeader":"<!-- begin field 9be4493d-84cd-4b68-80af-8f011350a90b --><h3>How should I manage treatment failure in a person with vulvovaginal candidiasis who is diabetic or immunocompromised?</h3><!-- end field 9be4493d-84cd-4b68-80af-8f011350a90b -->","summary":null,"htmlStringContent":"<!-- begin item 561563b2-ea3b-4684-84e5-399022e7d2f9 --><!-- begin field f7e0700a-5eeb-4e03-ade1-e8bf04b900eb --><ul><li><strong>If symptoms have not resolved within 7–14 days of initial treatment:</strong><ul><li><strong>Confirm that the <a class=\"topic-reference internal-reference\" href=\"/topics/candida-female-genital/management/diabetes-or-immunocompromised/#initial-management\">initial treatment</a> was used as recommended, but be aware that:</strong><ul><li>Topical treatments can cause vulvovaginal irritation, which may be mistaken for treatment failure. </li></ul></li><li><strong>Reassess </strong><strong>for other <a class=\"topic-reference internal-reference\" href=\"/topics/candida-female-genital/background-information/risk-factors/\">predisposing factors</a></strong> and remove or control as far as possible.</li><li><strong>Consider<em> </em></strong><strong><a class=\"topic-reference internal-reference\" href=\"/topics/candida-female-genital/diagnosis/differential-diagnosis/\">alternative diagnoses</a><em>. </em></strong>If appropriate:<ul><li>Send a vaginal specimen for microscopy, culture, and sensitivity. This may identify a moderate/heavy growth of <em>Candida albicans</em>, non-albicans <em>Candida </em>species, or a <a class=\"topic-reference internal-reference\" href=\"/topics/candida-female-genital/diagnosis/differential-diagnosis/\">mixed infection</a>.</li><li>Consider measuring vaginal pH (if possible) to assess the likelihood of symptoms being due to <em>Candida </em>(pH less than or equal to 4.5), bacterial vaginosis (pH above 4.5), or <em>Trichomonas vaginalis </em>(pH above 4.5).</li><li>Arrange other <a class=\"topic-reference internal-reference\" href=\"/topics/candida-female-genital/diagnosis/assessment/\">investigations</a> as clinically indicated.</li></ul></li><li><strong>Treat the person:</strong><ul><li>If there has been a lack of compliance with the initial treatment formulation, prescribe the alternative formulation (for example, prescribe oral treatment if there has been poor compliance with intravaginal treatment). </li></ul></li><li><strong>Reinforce <a class=\"topic-reference internal-reference\" href=\"/topics/candida-female-genital/management/diabetes-or-immunocompromised/#general-advice-on-self-management\">self-management advice</a></strong><strong>.</strong></li><li><strong>Refer or seek specialist advice if:</strong><ul><li>The woman is breastfeeding.</li><li>There is doubt about the diagnosis.</li><li>Symptoms are not improving and treatment failure is unexplained.</li><li>Non-albicans <em>Candida </em>species has been identified.</li><li>Treatment fails again.</li></ul></li></ul></li></ul><!-- end field f7e0700a-5eeb-4e03-ade1-e8bf04b900eb --><!-- end item 561563b2-ea3b-4684-84e5-399022e7d2f9 -->","subChapters":[{"id":"e78a9643-b8b9-5cf8-a55b-e168b7249a84","slug":"basis-for-recommendation-13a","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field ab2c0137-2010-4807-8437-0119b1af5b4b --><h4>Basis for recommendation</h4><!-- end field ab2c0137-2010-4807-8437-0119b1af5b4b -->","summary":null,"htmlStringContent":"<!-- begin item 13ac9cbd-7119-4247-aa37-e974e390dad8 --><!-- begin field 2b14e865-fb7f-4fad-84cb-c9d6edba2d2e --><p>CKS found no evidence or national guidelines specifically on treatment failure of vulvovaginal candidiasis in women who are diabetic or immunocompromised. These recommendations are largely based on what CKS considers to be good clinical practice.</p><h5>Confirming compliance with initial management </h5><ul><li>CKS recommends considering compliance with initial management, as treatment failure is more likely if there is poor compliance [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">Ringdahl, 2000</a>].</li><li>Topical antifungals usually cause no systemic adverse effects, although local mild burning or irritation may occur [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">BASHH, 2007b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">CDC, 2015</a>]. CKS recommends considering this in women with persisting symptoms.</li></ul><h5>Reassessing for predisposing factors</h5><ul><li>CKS recommends reassessing for predisposing factors, as treatment failure is more likely if there is continued exposure to predisposing factors [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">Ringdahl, 2000</a>].</li></ul><h5>Considering alternative diagnoses</h5><ul><li>The symptoms of vulvovaginal candidiasis are non-specific and may occur in women with other conditions [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">BASHH, 2007b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">CDC, 2015</a>]. CKS recommends considering alternative diagnoses if there is treatment failure, as misdiagnosis is a common cause for treatment failure.</li><li>The recommendations to send a vaginal specimen for microscopy, culture, and sensitivity and to consider measuring vaginal pH (if possible) are extrapolated from expert opinion in UK and US guidelines [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">BASHH, 2006b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">BASHH, 2007b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">FSRH, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">RCGP, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">CDC, 2015</a>], which differ in their recommendations for laboratory tests for women with vulvovaginal candidiasis. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/candida-female-genital/diagnosis/assessment/#basis-for-recommendation-179\">Investigations</a> for more information.</li></ul><h5>Antifungal treatment</h5><ul><li>The recommendation on how to manage poor compliance is based on what CKS considers to be good clinical practice.</li></ul><h5>Referral or seeking specialist advice</h5><ul><li>The recommendation to arrange referral or seek specialist advice if the woman is breastfeeding is based on what CKS considers to be good clinical practice.<ul><li>The manufacturer advises that breastfeeding is not recommended after high-dose treatment with (or repeated use of) oral fluconazole, except for potentially life-threatening infections [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">ABPI, 2015c</a>], and itraconazole is not recommended for use in breastfeeding women [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">ABPI, 2016b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">BNF 72, 2016</a>].</li></ul></li><li>The recommendation to arrange referral or seek specialist advice if non-albicans <em>Candida</em> species is identified is based on expert opinion in guidelines issued by the British Association of Sexual Health and HIV (BASHH) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">BASHH, 2007b</a>] and the US Centers for Disease Control and Prevention (CDC) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">CDC, 2015</a>], which state that:<ul><li>The optimal treatment of non-albicans vulvovaginal candidiasis is currently unknown. Options include longer duration of treatment (7–14 days) with a non-fluconazole azole regimen (oral or topical) as first-line treatment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">CDC, 2015</a>].</li><li>In some people with resistant organisms, treatments that should only be initiated by a specialist, or are difficult to obtain in primary care, may be required [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">BASHH, 2007d</a>].</li></ul></li><li>The other recommendations on when to arrange referral or seek specialist advice are based on what CKS considers to be good clinical practice.</li></ul><!-- end field 2b14e865-fb7f-4fad-84cb-c9d6edba2d2e --><!-- end item 13ac9cbd-7119-4247-aa37-e974e390dad8 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}